Publicacións en colaboración con investigadores/as de Hospital Vall d'Hebron (26)

2024

  1. Hyponatremia after COVID-19 is frequent in the first year and increases re-admissions

    Scientific Reports, Vol. 14, Núm. 1

  2. The role of HBIG in real life for patients undergoing liver transplantation due to HDV-related cirrhosis

    Liver International, Vol. 44, Núm. 2, pp. 279-285

2022

  1. Incidence and risk factors for early readmission after hospitalization for SARS-CoV-2 infection: results from a retrospective cohort study

    Infection, Vol. 50, Núm. 2, pp. 371-380

2021

  1. Covid-19 clinical profile in latin american migrants living in spain: Does the geographical origin matter?

    Journal of Clinical Medicine, Vol. 10, Núm. 22

  2. Low seroprevalence of SARS-CoV-2 antibodies in a liver transplant cohort

    Transplant International, Vol. 34, Núm. 10, pp. 1908-1913

  3. The role of liver steatosis as measured with transient elastography and transaminases on hard clinical outcomes in patients with COVID-19

    Therapeutic Advances in Gastroenterology, Vol. 14

2020

  1. Proceedings of the 25th annual congress of the international liver transplantation society

    Transplantation, Vol. 104, Núm. 8, pp. 1560-1565

  2. Recipient Age for Liver Transplantation: Should It Be Limited? A Propensity Score Matching Analysis of a Large European Series

    Transplantation Proceedings, Vol. 52, Núm. 5, pp. 1442-1449

2017

  1. Sofosbuvir and daclatasvir in mono-and HIV-coinfected patients with recurrent hepatitis C After liver transplant

    Annals of Hepatology, Vol. 16, Núm. 1, pp. 86-93

2016

  1. Human immunodeficiency virus infection does not worsen prognosis of liver transplantation for hepatocellular carcinoma

    Hepatology, Vol. 63, Núm. 2, pp. 488-498

  2. Impact of cytomegalovirus infection on severe hepatitis c recurrence in patients undergoing liver transplantation

    Transplantation, Vol. 100, Núm. 3, pp. 593-599

  3. Treatment of severe recurrent hepatitis C after liver transplantation in HIV infected patients using sofosbuvir-based therapy

    Alimentary Pharmacology and Therapeutics, Vol. 43, Núm. 12, pp. 1319-1329

2015

  1. Doubtful role of IL28B polymorphism in occult Hepatitis B infection

    Intervirology, Vol. 58, Núm. 3, pp. 160-165

2014

  1. Cirrhosis, liver transplantation and HIV infection are risk factors associated with hepatitis E virus infection

    PLoS ONE, Vol. 9, Núm. 7

  2. Etiology and mortality of spontaneous bacterial peritonitis in liver transplant recipients: A cohort study

    Liver Transplantation, Vol. 20, Núm. 7, pp. 856-863

2012

  1. IL28B genetic variation and hepatitis C virus-specific CD4+ T-cell responses in anti-HCV-positive blood donors

    Journal of Viral Hepatitis, Vol. 19, Núm. 12, pp. 867-871

  2. Incidence, characteristics and risk factors of marked hyperbilirubinemia after allogeneic hematopoietic cell transplantation with reduced-intensity conditioning

    Bone Marrow Transplantation, Vol. 47, Núm. 10, pp. 1343-1349

  3. Reversal of nonstructural protein 3-specific CD4 + T cell dysfunction in patients with persistent hepatitis C virus infection

    Journal of Viral Hepatitis, Vol. 19, Núm. 4, pp. 283-294

  4. Transjugular intrahepatic portosystemic shunt for the treatment of sinusoidal obstruction syndrome in a liver transplant recipient and review of the literature

    Liver Transplantation, Vol. 18, Núm. 2, pp. 201-205

  5. Twelve-week posttreatment follow-up to predict sustained virologic response for recurrent hepatitis C infection in liver recipients

    Transplantation, Vol. 93, Núm. 4, pp. 450-453